Methazolamide is a carbonic anhydrase inhibitor used to treat open angle glaucoma and acute angle closure glaucoma. A medication used to treat glaucoma, a high level of pressure in the eye.
- Mechanism
- Curator reviewed
Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
- Primary indication
- For treatment of chronic open-angle glaucoma and acute angle-closure glaucomaCurator reviewed · 2 structured indications
- Formula / weight
- C5H8N4O3S2 · 236.26 g/mol (avg)
- First approval
- Canada, 1998 · United States, 1993
- Also known as
- Methenamide · Neptazaneat
- Code names
- L-584601 · VVP-808
Resolves to
Clinical / RWD
Structure
InChIKey
FLOSMHQXBMRNHR-QPJJXVBHSA-NSMILESCN1N=C(S\C1=N\C(C)=O)S(N)(=O)=OTransporters
What you can answer from here — as of September 20, 2026
5Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Methazolamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account